Nizatidine: Difference between revisions
Added mention of US trade name Axid. |
|||
| Line 47: | Line 47: | ||
Nizatidine was developed by [[Eli Lilly]], and was first marketed in [[1987]]. It is considered to be equipotent with [[ranitidine]] and differs by the substitution of a [[thiazole]]-ring in place of the [[furan]]-ring in ranitidine. |
Nizatidine was developed by [[Eli Lilly]], and was first marketed in [[1987]]. It is considered to be equipotent with [[ranitidine]] and differs by the substitution of a [[thiazole]]-ring in place of the [[furan]]-ring in ranitidine. |
||
Nazitidine proved to be the last new histamine H<sub>2</sub>-receptor antagonists introduced prior to the advent of [[proton pump inhibitor]]s. |
Nazitidine proved to be the last new histamine H<sub>2</sub>-receptor antagonists introduced prior to the advent of [[proton pump inhibitor]]s. It is available [[over the counter]] in the United States, but generic equivalents are rare to nonexistent, somewhat hobbling its popularity in relation to the other drugs of the class. |
||
[[Category: H2 receptor antagonists]] |
[[Category: H2 receptor antagonists]] |
||
Revision as of 01:09, 15 August 2005
|
Molecular structure of nizatidine | |
| N-[2-(2-dimethylaminomethylthiazol- 4-ylmethylthio)ethyl]-N'-methyl- 2-nitrovinylidenediamine | |
| CAS number 66357-35-5 |
ATC code |
| Chemical formula | C12H21N5O2S2 |
| Molecular weight | 331.5 |
| Bioavailability | >70% |
| Metabolism | hepatic |
| Elimination half-life | 1-1.5 hours |
| Excretion | renal |
| Pregnancy category | B3 (Australia) |
| Legal status | Schedule 4 (Australia) POM (UK) |
| Routes of administration | oral |
Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It was developed by Eli Lilly and is marketed under the trade names Tazac and Axid.
Clinical use
Main article: H2-receptor antagonist
History and development
Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole-ring in place of the furan-ring in ranitidine.
Nazitidine proved to be the last new histamine H2-receptor antagonists introduced prior to the advent of proton pump inhibitors. It is available over the counter in the United States, but generic equivalents are rare to nonexistent, somewhat hobbling its popularity in relation to the other drugs of the class.